← Leaderboards
Kimberly J Payne
Children'S Hospital Los Angeles
$2,021,603
Attributed
$2,943,846
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $452.2K · FY2005–19$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,943,846 · 5
By mechanism
R01$1,548,293 · 1
K01$626,102 · 1
R21$345,597 · 1
R43$296,194 · 1
F32$127,660 · 1
Top collaborators
- Sinisa Dovat5 shared
- Cathy A Swindlehurst2 shared
Most similar at Children'S Hospital Los Angeles
Same institution · by research overlap
- Gay Miriam Crooks$19,471,318
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoXenograft ModelGene ExpressionCell CycleHigh RiskCellsRelapseBone MarrowReceptorB-LymphocytesChildChildhoodXenograft ProcedureCell ProliferationCytokine ReceptorsSamplingMolecularMalignant Childhood NeoplasmPathway InteractionsImmuneLatinoDefectEngineeringLeukemia
Grant awards (18)
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$349,730
R01 · FY2019 · CA · contact PI
Administrative Supplement to: Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$102,422
R01 · FY2019 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$360,547
R01 · FY2018 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$360,547
R01 · FY2017 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$375,047
R01 · FY2016 · CA · contact PI
Xenograft Model to Study Impact of CRLF2-Ligand in Hispanic Childhood B-ALL$151,804
R21 · FY2013 · CA · contact PI
Development of novel small molecule drugs for the treatment of high risk B-ALL$93,796
R43 · FY2013 · CA
Development of novel small molecule drugs for the treatment of high risk B-ALL$202,398
R43 · FY2012 · CA
Xenograft Model to Study Impact of CRLF2-Ligand in Hispanic Childhood B-ALL$193,793
R21 · FY2012 · CA · contact PI
IL-7 in Human B1 and B2 Lymphocyte Differentiation$138,375
K01 · FY2008 · DK · contact PI
IL-7 in Human B1 and B2 Lymphocyte Differentiation$138,375
K01 · FY2007 · DK · contact PI
IL-7 in Human B1 and B2 Lymphocyte Differentiation$105,115
K01 · FY2006 · DK · contact PI
IL-7 in Human B1 and B2 Lymphocyte Differentiation$22,000
K01 · FY2006 · DK · contact PI
IL-7 in Human B1 and B2 Lymphocyte Differentiation$123,957
K01 · FY2005 · DK
IL-7 in Human B1 and B2 Lymphocyte Differentiation$98,280
K01 · FY2004 · DK
IKAROS ISOFORMS IN EARLY STAGES OF HUMAN HEMATOPOIESIS$48,148
F32 · FY2002 · DK
IKAROS ISOFORMS IN EARLY STAGES OF HUMAN HEMATOPOIESIS$41,996
F32 · FY2001 · DK
IKAROS ISOFORMS IN EARLY STAGES OF HUMAN HEMATOPOIESIS$37,516
F32 · FY2000 · DK